Genomic Intelligence
Genome2Protocol queries global population genomic datasets to estimate patient availability before site activation. By harmonizing distributed genomic information, it helps life sciences organizations plan trials faster, reduce wasted effort, and make confident, data-driven decisions in precision medicine.
Bridging Data Silos
Human Genome sequencing has accelerated 1000x and millions of genomes are catalogued around the world, yet Pharma still struggles to find the right patients for their clinical trials. Data fragmentation, standards mismatch, and siloed sources block access. Genome2Protocol connects these datasets to make precision medicine trials feasible.
Semantic Interoperability
Genome2Protocol combines AI, semantics, and standards to create a multiplier effect on fragmented data. AI interprets trial protocols and genomic variants, semantics map eligibility criteria to genomic profiles, and standards ensure interoperability across datasets. Together, they transform disconnected sources into a coherent, queryable layer for reliable patient estimation.
Where Genome2Protocol Fits in the Clinical Trial Ecosystem?
Genome2Protocol sits upstream of traditional clinical trial recruitment workflows. While most solutions operate post-activation using hospital EHR data, Genome2Protocol is genomics-native and designed for pre-activation feasibility.
It complements CRO-led feasibility assessments and EHR-based recruitment platforms by answering a different question, earlier: whether eligible patients exist at all, based on population-scale genomic data.
By querying biobanks directly, without moving patient-level data, it introduces a privacy-preserving layer that connects fragmented datasets before any site is selected or resources are committed.
Impact on Trial Feasibility and Patient Representation
Genome2Protocol brings data-driven rigor to clinical trial feasibility, reducing uncertainty in patient availability and helping avoid costly delays and failed site activations.
It also addresses a structural imbalance in precision medicine. Genomic data has grown rapidly, but remains unevenly distributed and disconnected from trial design. As a result, patients who meet molecular criteria, especially in underrepresented populations, are often overlooked early in study planning.
By making population-scale genomic data visible and queryable before site activation, Genome2Protocol enables more reliable trial design and supports a more representative approach to patient inclusion.